Literature DB >> 21109512

Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer.

Toshimitsu Ohashi1, Masami Ohnishi, Shigeaki Tanahashi, Michinori Murai.   

Abstract

OBJECTIVE: We investigated the efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer, as an alternative to cisplatin and 5-fluorouracil.
METHODS: A total of 31 patients were enrolled in this study. S-1 was administered orally twice a day for 14 days followed by a 2-week rest. Nedaplatin was intravenously administered on day 4. If possible, two courses of chemotherapy were performed. The radiotherapy was started concurrently with the administration of S-1.
RESULTS: The overall complete response rate was 81%. The 2-year overall survival rate was 96%. The 2-year relapse-free survival rate was 94%. The main adverse events were hematological toxicity, mucositis and dermatitis.
CONCLUSIONS: Our findings suggest that this therapeutic regimen has either an equal or lower toxicity than the conventional cisplatin and 5-fluorouracil, and that it has equal efficacy with regard to the clinical response and short-term outcome. Moreover, it is possible to successfully perform this treatment in an outpatient setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109512     DOI: 10.1093/jjco/hyq196

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

1.  Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.

Authors:  Yuki Kawarada; Masayuki Miyazaki; Ayaka Itoh; Risa Araki; Hidetaka Iwamizu; Tomomi Kataoka; Yasuo Kumakura; Akiko Ota; Taku Nagai; Kiyofumi Yamada
Journal:  Int J Clin Oncol       Date:  2017-01-25       Impact factor: 3.402

2.  Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.

Authors:  Kensei Nakata; Koh-Ichi Sakata; Masanori Someya; Katsutoshi Miura; Junichi Hayashi; Masakazu Hori; Masaru Takagi; Tetsuo Himi; Atsushi Kondo; Masato Hareyama
Journal:  J Radiat Res       Date:  2013-01-04       Impact factor: 2.724

3.  Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Authors:  Muneaki Shimada; Hiroaki Itamochi; Junzo Kigawa
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

4.  Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma.

Authors:  Li Yin; Xiu-Hua Bian; Xue Wang; Meng Chen; Jing Wu; Jian-Hua Xu; Pu-Dong Qian; Wen-Jie Guo; Xue-Song Jiang; Huan-Feng Zhu; Jia-Jia Gu; Jian-Feng Wu; Ye-wei Zhang; Xia He
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

5.  Nedaplatin as a Single-Agent Chemotherapy May Support Palliative Therapy for Patients with Adenoid Cystic Carcinoma: A Case Report.

Authors:  Hiroyuki Hirakawa; Takayoshi Kiba; Yuko Saito; Yoshiteru Watanabe; Takahiro Suzuki; Nobuo Ota
Journal:  Case Rep Oncol       Date:  2017-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.